Secukinumab for treating moderate to severe plaque psoriasis in children and young people

2.1 Secukinumab (Cosentyx, Novartis) has a marketing authorisation for 'the treatment of moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy'.

2.2 The dosage schedule is available in the summary of product characteristics.

2.3 The list price of secukinumab is £609.39 for a 150 mg/ml prefilled syringe (excluding VAT; BNF online, accessed August 2021).

2.4 The company has a commercial arrangement. This makes secukinumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.